NAGESHWARA V. DASARI to Humans
This is a "connection" page, showing publications NAGESHWARA V. DASARI has written about Humans.
Connection Strength
0.123
-
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023 07 01; 402(10395):41-53.
Score: 0.017
-
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors. Invest New Drugs. 2023 Jun; 41(3):421-430.
Score: 0.017
-
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol. 2020 12; 17(12):757-770.
Score: 0.014
-
Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study. Oncologist. 2019 08; 24(8):1066-1075.
Score: 0.013
-
Initial treatment of well-differentiated neuroendocrine tumors. Oncology (Williston Park). 2014 Nov; 28(11):945-7.
Score: 0.010
-
Gastrointestinal neuroendocrine tumors: slow but steady progress. Oncology (Williston Park). 2014 Sep; 28(9):762-3.
Score: 0.009
-
A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. Invest New Drugs. 2013 Feb; 31(1):115-25.
Score: 0.008
-
Recurrent pancreatic adenocarcinoma after pancreatic resection. Oncology (Williston Park). 2010 Dec; 24(14):1329-34.
Score: 0.007
-
New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways. Clin Cancer Res. 2010 Aug 01; 16(15):3811-8.
Score: 0.007
-
Oxidative stress induces premature senescence by stimulating caveolin-1 gene transcription through p38 mitogen-activated protein kinase/Sp1-mediated activation of two GC-rich promoter elements. Cancer Res. 2006 Nov 15; 66(22):10805-14.
Score: 0.005
-
Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer. 2014 Sep; 13(3):164-71.
Score: 0.002
-
A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma. Invest New Drugs. 2014 Aug; 32(4):739-45.
Score: 0.002
-
Atypical metastatic presentations in colorectal cancer: a case series. Clin Colorectal Cancer. 2014 Mar; 13(1):e1-4.
Score: 0.002
-
Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. Invest New Drugs. 2013 Apr; 31(2):345-54.
Score: 0.002
-
Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib. Clin Cancer Res. 2012 May 01; 18(9):2704-14.
Score: 0.002
-
Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol. 2012 Jul 01; 30(19):2348-53.
Score: 0.002
-
ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a ?-secretase inhibitor and irinotecan in colorectal cancer. Mol Oncol. 2012 Jun; 6(3):370-81.
Score: 0.002